COPD is diagnosed with a breathing test called spirometry. Specifically, your ratio of air forced out in one second to total air exhaled must fall below 0.7 after inhaling a bronchodilator medication. This single measurement, taken after the bronchodilator opens your airways as much as possible, is the mandatory requirement for confirming a COPD diagnosis. But reaching that number is only one piece of a process that typically involves a physical exam, symptom questionnaires, imaging, and sometimes blood work.
What Spirometry Measures and Why It Matters
Spirometry is the cornerstone of COPD diagnosis. You breathe into a mouthpiece as hard and fast as you can, and the device records two key numbers: how much air you can force out in the first second (called FEV1) and the total volume of air you can exhale in one full breath (called FVC). The ratio between them tells your doctor whether your airways are obstructed.
A healthy pair of lungs can push out most of their air in that first second. When the ratio drops below 0.7, it means air is getting trapped, which is the hallmark of COPD. Crucially, this test must be done after you inhale a short-acting bronchodilator. The medication relaxes your airway muscles temporarily, and if obstruction persists even with that help, it points toward COPD rather than a reversible condition like an asthma flare.
One common misconception is that a big improvement after the bronchodilator rules out COPD and points to asthma instead. Research in three large population studies found that about 18% of people with COPD showed the same degree of improvement (a 12% and 200 mL jump in FEV1) that is traditionally considered a hallmark of asthma. Around 17% of people with confirmed asthma showed that same response. So the bronchodilator test alone cannot reliably distinguish the two conditions. Your doctor will weigh the full clinical picture.
How Severity Is Graded
Once COPD is confirmed, spirometry also determines how advanced it is. The international GOLD classification uses your FEV1 as a percentage of what’s predicted for someone your age, sex, and height:
- GOLD 1 (mild): FEV1 is 80% or more of predicted. Many people at this stage don’t realize anything is wrong.
- GOLD 2 (moderate): FEV1 is 50% to 79% of predicted. Shortness of breath during everyday activities usually becomes noticeable here.
- GOLD 3 (severe): FEV1 is 30% to 49% of predicted. Breathlessness limits daily routines significantly.
- GOLD 4 (very severe): FEV1 is below 30% of predicted. Even light activity can feel overwhelming.
These stages guide treatment decisions, but they don’t capture the full picture. Two people with the same FEV1 percentage can feel very different day to day, which is why doctors also assess symptoms separately.
Symptom Questionnaires
Spirometry tells your doctor how much airflow you’ve lost. Symptom questionnaires tell them how much that loss affects your life. Two standardized tools are used most often.
The mMRC dyspnea scale is a simple five-point rating of your breathlessness, from “I only get breathless with strenuous exercise” (grade 0) to “I’m too breathless to leave the house or get dressed” (grade 4). A score of 2 or higher, meaning you walk slower than people your age on flat ground because of breathlessness, is considered a marker of more prominent symptoms.
The CAT score is broader. It covers eight areas: breathlessness, exercise capacity, cough, mucus production, chest tightness, sleep quality, energy, and confidence leaving home. Each is rated 0 to 5, for a total possible score of 40. A score of 10 or above signals that COPD is meaningfully affecting your quality of life. Scores of 15 and above correlate with more severe breathlessness, and scores above 20 tend to match people who struggle with almost any physical activity.
Together, the spirometry stage and symptom scores determine which treatment group you fall into, so filling out these questionnaires honestly makes a real difference in the care you receive.
What the Physical Exam Reveals
Before ordering any tests, your doctor will look and listen for physical signs of airflow obstruction. No single sign confirms COPD on its own, but several together build a strong case.
Breath sounds are among the most telling clues. Reduced breath sound intensity, where your breathing simply sounds quieter than expected through a stethoscope, strongly suggests chronic airflow obstruction. Early inspiratory crackles, brief crackling sounds at the very start of a breath, are particularly associated with severe obstruction. Wheezing during normal (unforced) breathing also raises suspicion.
Chest shape can change over time. Normally, your chest is wider side to side than it is front to back. In advanced COPD, air trapping gradually inflates the lungs beyond their normal size, pushing the ribcage outward until the front-to-back dimension nearly matches the side-to-side dimension. This is often called a barrel chest. Tapping on a hyperinflated chest produces a hollow, drum-like sound called hyperresonance, which is one of the strongest physical predictors of COPD, with a specificity above 97%.
Your doctor may also watch how you breathe. Pursed-lip breathing, where you exhale through tightly pressed lips almost like blowing out a candle, is a common unconscious strategy people with COPD develop to keep airways open longer. Use of neck and shoulder muscles to help with breathing is an early sign of obstruction and, when prominent, suggests FEV1 has dropped to around 30% of normal or less. Another sign, called Hoover’s sign, is a visible inward pull of the lower ribcage during inhalation instead of the normal outward expansion.
Imaging Tests
A chest X-ray is often the first imaging test, mainly to rule out other causes of breathlessness like lung cancer, heart failure, or pneumonia. It can show hyperinflated lungs, but it isn’t sensitive enough to confirm or grade COPD.
A CT scan provides much more detail. It can identify the specific type of emphysema present: centrilobular emphysema appears as small round areas of destroyed tissue, often in the upper lungs and strongly linked to smoking; panlobular emphysema affects the entire air sac structure more uniformly and is associated with a genetic deficiency (more on that below); paraseptal emphysema clusters near the outer edges of the lungs. CT also reveals bronchial wall thickening, a marker of the chronic bronchitis component of COPD, reflecting airway remodeling and excess mucus production. These findings help your care team understand which type of lung damage is dominant, which can influence treatment choices.
CT scans are not required for every COPD diagnosis. They’re most useful when spirometry results are borderline, symptoms don’t match the numbers, or your doctor suspects complications like large air pockets (bullae) that might need attention.
Blood Gas Testing in Advanced COPD
For people with severe or very severe COPD, a blood sample drawn from an artery (usually at the wrist) measures oxygen and carbon dioxide levels directly. This test helps detect respiratory failure, which is defined as an oxygen level below 60 mmHg.
There are two patterns. In the first type, oxygen is low but carbon dioxide stays normal or low, meaning your lungs still move air but can’t exchange gases efficiently. In the second type, oxygen drops below 60 mmHg while carbon dioxide rises above 45 mmHg, meaning the lungs are no longer ventilating well enough to clear carbon dioxide. The second type is more dangerous and often signals the need for supplemental oxygen or assisted breathing support. This test isn’t part of early-stage diagnosis but becomes important for managing advanced disease and deciding whether home oxygen therapy is needed.
Genetic Testing for Alpha-1 Antitrypsin Deficiency
About 1% to 2% of COPD cases stem from an inherited condition where the body doesn’t produce enough of a protein that protects lung tissue from damage. Current guidelines recommend testing for this deficiency at the time of COPD diagnosis, especially if you developed COPD at a young age, have minimal smoking history, or if emphysema appears predominantly in the lower lungs (an unusual pattern for smoking-related disease). Testing is also recommended for adults with persistent asthma-like obstruction or unexplained widening of the airways (bronchiectasis).
The initial test is a simple blood draw measuring the protein level. If it falls below a certain threshold, genetic sequencing identifies the specific mutation. Because this is an inherited condition, first-degree relatives of anyone with an abnormal gene are typically offered genetic counseling and testing as well. Identifying the deficiency matters because a targeted treatment exists that replaces the missing protein, and because standard COPD management alone may not be enough.
Putting It All Together
COPD diagnosis is not a single test but a layered process. It starts with your history and physical exam, gets confirmed by spirometry showing a post-bronchodilator FEV1/FVC ratio below 0.7, and is then refined through severity grading, symptom scoring, imaging when needed, and blood work in advanced cases. Each layer adds practical information: spirometry says whether obstruction exists, the GOLD stage says how much lung function remains, symptom scores say how your daily life is affected, and imaging reveals which type of lung damage is driving the problem. The combination shapes a treatment plan that fits your specific situation rather than a one-size-fits-all approach.